Edition:
United Kingdom

Capricor Therapeutics Inc (CAPR.OQ)

CAPR.OQ on NASDAQ Stock Exchange Capital Market

1.77USD
21 Feb 2018
Change (% chg)

$0.01 (+0.57%)
Prev Close
$1.76
Open
$1.75
Day's High
$1.83
Day's Low
$1.75
Volume
14,100
Avg. Vol
130,738
52-wk High
$4.25
52-wk Low
$0.63

Latest Key Developments (Source: Significant Developments)

Capricor Therapeutics Appoints Anthony Bergmann As CFO, Eff Jan 1, 2018 - SEC Filing
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS INC SAYS HAS APPOINTED ANTHONY BERGMANN AS CHIEF FINANCIAL OFFICER, EFFECTIVE JANUARY 1, 2018 - SEC FILING.CAPRICOR THERAPEUTICS INC - ON DEC 20, LELAND GERSHELL GAVE NOTICE OF HIS RESIGNATION AS CHIEF FINANCIAL OFFICER OF COMPANY, EFFECTIVE JANUARY 1, 2018.  Full Article

Capricor & California Institute For Regenerative Medicine​ Entered Into Amendment 3 To CIRM Notice Loan Award
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR SAYS ‍ON DEC 11, CO, CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE​ ENTERED INTO AMENDMENT NO. 3 TO CIRM NOTICE OF LOAN AWARD - SEC FILING.CAPRICOR SAYS PURSUANT TO AMENDMENT, TOTAL LOAN BALANCE UNDER LOAN AWARD FORGIVEN BY CIRM, TERMINATING UNIT, CO'S OBLIGATION TO REPAY LOAN BALANCE​.CAPRICOR - ‍DECISION TO TERMINATE LOAN AWARD AND FORGIVE LOAN BALANCE WAS DUE TO ABANDONMENT OF ALLSTAR PROJECT AT END OF PROJECT PERIOD​.  Full Article

Capricor Therapeutics Says FDA Cleared IND Application For CAP-1002
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR CAP-1002.CAPRICOR THERAPEUTICS INC - POTENTIAL REGISTRATION TRIAL IN DUCHENNE MUSCULAR DYSTROPHY ON TRACK TO INITIATE IN Q1 OF 2018.CAPRICOR THERAPEUTICS-PLANS TO APPLY FOR REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR CAP-1002 BASED ON UPDATED GUIDANCE RECENTLY ISSUED BY FDA.  Full Article

Capricor Therapeutics reports Q3 loss per share $0.12
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Capricor Therapeutics Inc ::Capricor Therapeutics reports third quarter 2017 financial results and provides update on duchenne muscular dystrophy development program.Q3 loss per share $0.12.  Full Article

Capricor Therapeutics Q2 loss per share $0.26
Monday, 15 Aug 2016 

Capricor Therapeutics Inc : Capricor Therapeutics reports second quarter 2016 financial results and provides clinical update . Q2 loss per share $0.26 . Duchenne muscular dystrophy trial on track to report top-line six-month results in Q1 of 2017 .Expects existing cash, cash equivalents, marketable securities will fund research and development programs through Q1 of 2017.  Full Article

Capricor Therapeutics reports 12-month data from the dynamic clinical trial
Thursday, 16 Jun 2016 

Capricor Therapeutics : Says 1002 infusion was well-tolerated in dynamic trail .Reports Positive 12 Month data from the dynamic clinical trial.  Full Article

Capricor Therapeutics says sale of 846,073 shares
Tuesday, 14 Jun 2016 

Capricor Therapeutics Inc: Sale of 846,073 shares of common stock issuable upon exercise of outstanding warrants by selling stockholders - sec filing .Sale of up to 846,073 shares of common stock issuable upon exercise of warrants with exercise price of $4.50/share.  Full Article

Capricor Therapeutics Q1 loss per share $0.26
Thursday, 12 May 2016 

Capricor Therapeutics Inc : Capricor therapeutics provides corporate update and reports first quarter 2016 financial results .Q1 loss per share $0.26.  Full Article

Capricor Therapeutics announces $4 mln registered direct offering
Tuesday, 15 Mar 2016 

Capricor Therapeutics:Announces $4 Million Registered Direct Offering.Entered into a Subscription Agreement with certain investors for the purchase and sale of 1,692,151 shares of common stock at a price of $2.40 per share.  Full Article

BRIEF-Capricor Therapeutics Says ‍FDA Has Granted CAP-1002 RMAT Designation

* CAPRICOR THERAPEUTICS SAYS ‍FDA HAS GRANTED CAP-1002 REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION - SEC FILING Source text : (http://bit.ly/2s6RQ09) Further company coverage: